In Science this week: single-cell tools named Breakthrough of the Year winner, differences in gut microbiome composition and function in people with bowel disease, and more.
Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.
Australian researchers sequenced ancient and modern Aboriginal Australians to find long-term population continuity, which could help return remains to proper groups.
The New York Department of Health-certified tests are based on proprietary algorithms licensed from Columbia University, which offers them in the US.
The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.
The partners will leverage Singapore’s clinical network to collect a variety of 'omics data from consenting individuals and store the data for local researchers to investigate.
In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.
In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.
The firms will jointly invest in establishing a joint venture company in China, and Autobio has also invested €10 million in Mobidiag.
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.
The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.
60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.
In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.